Efficacy and safety of recombinant human activated protein C for severe sepsis.

By G. R. Bernard, J. L. Vincent, P. Laterre, S. Larosa, J. Dhainaut, A. López-Rodríguez, J. Steingrub, G. Garber, J. Helterbrand, E. W. Ely and 1 more. New England Journal of Medicine, 2001

5,337 citations recorded by the source corpus.

Subfields: Epidemiology, Hematology, Nephrology

View Paper: https://www.semanticscholar.org/paper/d9011ded31f064856988bb319e8d41e75b019b16

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Jean-Louis Vincent
2. D. Remick
3. Derek C. Angus
4. Mitchell M. Levy
5. Greg S. Martin
6. Ayumi Shintani
7. M. Moss
8. David M. Mannino

In Hematology

1. D. Remick
2. M. Levi
3. H. Versteeg
4. Pieter H. Reitsma
5. J. Heemskerk
6. C. Esmon
7. T. van der Poll
8. V. Ossovskaya

In Nephrology

1. S. Hughes
2. Jean-Louis Vincent

Citations in the corpus

• Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003* (2007, background): “Recent advances in the management of sepsis and critically ill patients, such as the use of low-dose corticosteroids for septic shock (40), intensive glucose control (41), the utilization of early goal-directed resuscitation in severe sepsis (42), and drotrecogin alpha (activated) (43), if widely ad”
• Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, neutral): “8%) of drotrecogin alfa activated treatment of patients in the CAP subgroup was equivalent to that in the subgroup with APACHE II scores 25 [92, 280, 281].”
• Epidemiology of sepsis in Germany: results from a national prospective multicenter study (2007, background): “mortality rates (ranging between 31 and 39%) were much lower [23, 24, 25].”
• 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference (2003, background): “For example, an indicator of dysregulation of the coagulation system might be more valuable for making a decision about whether to institute therapy with drotrecogin α (activated) [36], whereas a marker of adrenal dysfunction might be more useful for determining whether to institute ther-”
• Current epidemiology of septic shock: the CUB-Réa Network. (2003, background): “Recent Phase III trials suggested survival benefit from human recombinant activated protein C in patients with severe sepsis and at least one organ dysfunction (10) and from low-dose steroids in patients with septic shock with presumed adrenal dysfunction (11).”
• Mode of death after admission to an intensive care unit following cardiac arrest (2004, methodology): “Physiological criteria for other organ dysfunctions were taken from the PROWESS study of drotrecogin alfa (activated) [5].”
• The effect of age on the development and outcome of adult sepsis* (2006, background): “The limited available evidence regarding sepsis therapies in the elderly suggests that these therapies are similarly effective at improving survival (42, 43).”